Abstract: A gastric ulcer therapeutic agent comprising as an active ingredient a composite hydroxide of a hydrotalcite and an aluminum hydroxide compound, which composite hydroxide is represented by the formula (1), Mg1-xAlx(OH)2+x-ny(An-)y(H2O)m??(1), wherein An-represents an anion, n represents a valence of the anion in the range of 1 to 4, x is in the range of 0.34<x<0.7, y is in the range of 0<y<0.8, and m is in the range of 0<m<4.

Abstract: A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics.

Abstract: The present invention generally relates to methods and compositions for treating pathogenic vaginal biofilms. More specifically, the invention relates to pharmaceutical compositions comprising a combination of boric acid and diethylaminetetracetic acid (EDTA) and to methods of using such compositions to treat or prevent biofilm formation associated with vaginal infections, such as bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), trichomoniasis or mixed infections.

Abstract: Methods of preparing compositions for preferential distribution of active agents to injury sites are provided. The compositions may comprise a polymer with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature. Methods of identifying suitable components for such compositions are also disclosed.

Abstract: A contact lens disinfecting solution that comprises 0.5 wt. % to 6 wt. % hydrogen peroxide, or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound. The presence of the P-metal modulating compound in the disinfecting hydrogen peroxide solution slows the rate at which the hydrogen peroxide is neutralized, particularly during the initial two hours, by a catalyst element that includes a P-metal. This reduction in rate of peroxide neutralization provides a more effective solution for killing certain microorganisms and fungi.

Abstract: The present application relates to a facial and/or body wash composition that after rinsing provides a sun protection factor of at least about 6 comprising (i) red petrolatum; (ii) at least one surface-treated metal oxide pigment that blocks ultraviolet radiation in the wavelength range of from about 290 nm to about 400 nm; (iii) at least one organic sunscreen agent having a log P of greater than about 4.0 that blocks or absorbs ultraviolet radiation in the wavelength range of from about 290 nm to about 400 nm; (iv) at least one lathering anionic surfactant; (v) at least one lathering non-ionic surfactant; (vi) an alkyl silicone; and (vii) a volatile cyclic silicone.

Abstract: Swellable and degradable microspheres are described. The microspheres are prepared by a process that is reliable and high yielding, and makes use of a low temperature azo initiator, a small molecule chlorinated solvent as the organic phase, and a heat treatment step, and is carried out in absence of a crosslinking agent. The microsphere preparation made using the process is particularly useful as a degradable embolic material.

Abstract: An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, a bulk density is less than 0.54 g/mL, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.9 meq/g is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably reducing an amount of urinary proteins excretion.

Abstract: A multiphase personal care composition that comprises a structured surfactant phase and an oil continuous benefit phase. The structured surfactant phase comprises from about 5% to about 30% of a mixture of lathering surfactants, a lamellar inducing agent and a cationic polymer. The oil continuous benefit phase comprises a hydrocarbon based benefit material and a low HLB emulsifier. The low HLB emulsifier comprises an unsaturated monoglyceryl ester having from about 14 to about 30 carbon atoms. The oil continuous benefit phase comprises a ratio of said hydrocarbon based benefit materials to said low HLB emulsifier comprising from about 30:1 to about 200:1.

Abstract: Absorbent articles provided with an odor control system. The odor control system includes at least two classes of odor control materials, wherein one class acts on malodors or a malodorous substance in the absorbent article and a second class acts on nose receptors. The classes of odor control materials may be selected to provide a synergistic effect in terms of malodor reduction.

Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. In one aspect, the invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides methods of treating or preventing osteoarthritis by administering to a mammal, preferably via intraarticular injection, one or more compositions of the invention.

Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. The invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides methods of treating or preventing osteoarthritis by administering to a mammal, preferably via intraarticular injection, one or more compositions of the invention.

Abstract: The present invention relates to the field of perfumery and more particularly to the field of malodor counteractancy. In particular, it relates to a method for application of malodor counteracting (MOC) compositions capable of neutralizing in an efficient manner, through chemical reactions, malodors of a large variety of origins and which can be encountered in the air, on textiles, bathroom or kitchen surfaces, and the like. The composition may be applied as is or in the form of a perfuming composition or in a consumer product or article containing the compound or perfume composition.

Abstract: A broad spectrum antimicrobial composition consisting essentially of an iodopropynyl compound in combination with a benzimidazole and a metal borate is disclosed. The composition can be used to protect industrial systems against microbial growth and, more particularly, to protect substrates such as paints, coatings, stucco, concrete, stone, cementaceous surfaces, wood, wood-plastic composites, caulking, sealants, textiles, leather, wood, preservatives, metal working fluids, drilling muds, clay slurries, glazes, optical brighteners, carpet backing, and pigments against microbial growth. The composition can be used as a preservative for aqueous products.

Abstract: Disclosed is a transdermal preparation containing a hydrophobic drug. As a method of continuing the high drug permeation, it is used an unique hydrophilic polymer system in which the drug can be contained in a high concentration under no water environment, a solubility of the hydrophobic drug is decreased as the water is introduced to the patch from the skin, so that the drug is maintained at the saturation concentration even though the drug content is decreased as the drug is permeated to the skin. During the application of the transdermal preparation to the skin, it is possible to continuously permeate the high amount of drug, to maintain the sufficient adhesion during the use and to minimize the skin side effect, because the hydrophilic polymer absorbs the water from the skin. The hydrophilic polymer system can serve the function thereof through the hydrophobic adhesive layer capable of preventing the water quickly absorbed from the skin from being evaporated to the outside of the patch.

Abstract: The present invention relates to a controlled release carrier system that can be incorporated into rinse-off application products containing at least one surfactant such as heavy duty liquids (HDL), Rinse Cycle Fabric Softeners (RCFS), Shampoos, Hair Conditioners, Shower Gels, cleansing products, and that enhance deposition of lipophilic active materials like fragrance, fine perfumes, flavors and other volatile compounds onto a surface. The fragrance composition is encapsulated within a shell comprising a silicon-containing material and the shell has a mean diameter size which is lower than 30 micrometer. The surfactant composition containing the fragrance composition is washed off and the fragrance is progressively released.

Abstract: The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight.

Abstract: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an ? adrenergic receptor agonist selected from selective ?1 adrenergic receptor agonist, selective ?2 adrenergic receptor agonist, non-selective ?1/?2 adrenergic receptor agonist, agents with ?2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.

Abstract: An improved method and apparatus for producing a stable, non-toxic, antimicrobial electrolyzed saline solution with a broad range of anti-infective and therapeutic applications. The resulting electrolyzed saline solution exhibits a marked lack of toxicity upon intravenous, aspired, oral or topical application in mammals for therapeutic applications providing a broad platform, including topical disinfection, antimicrobial application, wound treatment, oxidative stress reduction and enhancement of immune function to better detect malfunctioning cells.

Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.